Last updated on November 2019

The XENERA 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread

Brief description of study

The main objective of the trial is to assess the anti-tumor activity of xentuzumab in combination with everolimus and exemestane over everolimus and exemestane in patients with HR+/ HER2- advanced or metastatic breast cancer and non-visceral disease.

Clinical Study Identifier: NCT03659136

Find a site near you

Start Over

Utah Cancer Specialists Cancer Center

Salt Lake City, UT United States
  Connect »